We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
As a result of the COVID-19 pandemic, the FDA has extended its enforcement discretion policy for six months for manufacturers of stem cell products to submit marketing applications to the FDA. Read More
Based on the results of a phase 2 trial, UK-based Synairgen said Monday that its antiviral SNG001 reduced the risk of severe disease in hospitalized COVID-19 patients. Read More
The British government announced Monday that it has reached COVID-19 vaccine supply deals with Pfizer/BioNTech and Valneva, locking in tens of millions of doses of their vaccine candidates for the country. Read More
In a first glimpse at the efficacy of a COVID-19 vaccine from AstraZeneca and the University of Oxford, highly anticipated clinical data found that it produces strong immune response. Read More
Hospira’s McPherson, Kansas manufacturing plant was cited for numerous deficiencies found during an FDA inspection, many of them repeat issues from an earlier inspection. Read More
Once hailed by President Trump and others as a possible treatment for COVID-19, the antimalarial drug hydroxychloroquine continues to a thumbs down in a number of human studies, most recently for treatment of patients with mild infections and for hospitalized patients. Read More
Democrats on the House’s coronavirus crisis subcommittee have launched an investigation into federal contracts for producing drugs, drug ingredients and supplies essential in the pandemic that they claim have been awarded to businesses politically tied to the Trump administration “without competition or transparency.” Read More